BHASHINI showcases Multilingual AI Innovations at NCeG 2026 (See 'Corp Brief') Freight Loading by Railways crosses 419 Million Tonnes in Q1 (See 'Corp Brief') IBC - Disciplinary proceedings initiated against RP are inseparably connected with underlying CIRP proceedings pending before NCLT & cannot be viewed in isolation from factual matrix giving rise to complaint: HC (See 'Legal Desk') MPEDA concludes Second National Skill Olympiad on Seafood Value Addition (See 'Corp Brief') Transition to E-mobility must focus on Green Growth: Yadav (See 'Corp Brief') NRAA-funded Wild Rice Conservation Project secures Major Milestone in Assam (See 'Corp Brief') Patent - Application for grant of patent rejected without assigning due reasoning; omitted to apply mandatory five-step inventive step laid down vide F. Hoffmann-La Roche Ltd. & Anr. v. Cipla Ltd.; case remanded: HC (See 'Legal Desk') Nagaland Minister discusses roadmap for expanding lavender related Agri-entrepreneurship (See 'Corp Brief') MECON Achieves Miniratna Category-I Status with Net Worth Surpassing Rs 535 Crore (See 'Corp Brief') India achieves Major Milestone with Approval of Country's First Procedure for Helicopter Operations (See 'Corp Brief') CCI approves acquisition of equity of Royal Challengers by a consortium (See 'Corp Brief') Trade Marks - While Section 9(1)(a) bars registration of marks devoid of distinctive character, distinctiveness is to be assessed w.r.t the goods & not in abstract; composite marks must be evaluated as a whole: HC (See 'Legal Desk') CCI approves acquisition of shares in Krazybee Services and Finnovation Tech by Mars Equity Dragon Fund (See 'Corp Brief') CCI approves combination of 7 SPVs by Anantam Highways to Build India Infrastructure Fund (See 'Corp Brief') CCI okays combination of Nippon Life by DWS Group GmbH (See 'Corp Brief') CGST Delhi observes GST Pakhwada 2026 with stakeholder outreach (See 'Corp Brief') Arbitration and Conciliation - Writ court's intervention is unwarranted where arbitral award is reasoned, plausible and not perverse in any manner: HC (See 'Legal Desk') Railways approves Rs 499 Crore Mansi-Saharsa Doubling Project (See 'Corp Brief') Five New Sub-Regional Offices of ESIC to be set up across India (See 'Corp Brief') Govt extends full customs duty exemption on critical petrochemical products (See 'Corp Brief') Contempt of Court - Contempt jurisdiction cannot be invoked based on expansive or alternative interpretation of Court's orders - only clear, explicit & willful disobedience can be penalised: HC (See 'Legal Desk') CEA organizes All-India Electrical Safety awareness programme (See 'Corp Brief') Regional industries must become partners in Viksit Bharat journey: RM (See 'Corp Brief') Union Minister reviews MSME Schemes in Ladakh (See 'Corp Brief') Competition Act - Allegation pertaining to a service dispute between a user & a platform service provider w.r.t. subscription management, cancellation of service & compensation, does not come under ambit of Section 4 of the Act: CCI (See 'Legal Desk') MPEDA to organise Second National Seafood Skill Olympiad during Seafood Expo Bharat 2026 (See 'Corp Brief') India's Space and Biotechnology Sectors present new collaboration opportunities: MoS (See 'Corp Brief') IPR - After pronouncement of final judgment and decree under Order XX CPC, Court becomes functus officio and cannot grant liberty for post-decree impleadment of mirror/redirect/alphanumeric websites: HC (See 'Legal Desk') Office of Principal Scientific Adviser signs MoU with Data Security Council of India (See 'Corp Brief') Telangana strengthens Clean Cities Through Behaviour Change and Citizen Action (See 'Corp Brief') IPR - If essential and dominant feature of earlier mark is fully contained in later mark, and later mark is only pluralized form that conveys same meaning, later mark can be held deceptively similar: HC (See 'Legal Desk') JP Nadda To Release Guidelines For 'Anaemia Mukt Bharat Abhiyaan' Today (See 'Corp Brief') A&C - Restraint on alienation of assets cannot be imposed when such relief was neither specifically sought nor argued in Section 17 application: HC (See 'Legal Desk') Environment Minister inaugurates workshop on tiger reintroduction in Sariska (See 'Corp Brief') JP Nadda to unveil healthcare programme for children up to three years (See 'Corp Brief') A&C - Scope of scrutiny u/s 11 is confined to prima facie examination of existence of arbitration agreement & does not extend to adjudication of disputed questions of fact or law: HC (See 'Legal Desk') Tech Innovation and disruption in Construction Industry (See 'CORP EINSICHT')

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.